press_release/
45 pages · Updated July 26, 2026
Pages
- abbvie-launches-strategic-collaboration-with-hotspot-therapeutics-to-further-expand-immunology-pipeline.html
- HotSpot Therapeutics Presents Preclinical Data from Small Molecule CBM Signalosome Inhibitor Program at ESMO Gastrointestinal Cancers Congress 2025 - HotSpot Therapeutics
- HotSpot Therapeutics Completes $45 Million Series A Financing to Advance New Approach to Allosteric Drug Discovery - HotSpot Therapeutics
- HotSpot Therapeutics Presents Preclinical Data from Small Molecule IRF5 Inhibitor Program at EULAR 2026 - HotSpot Therapeutics
- AbbVie Launches Strategic Collaboration with HotSpot Therapeutics to Further Expand Immunology Pipeline - HotSpot Therapeutics
- HotSpot Therapeutics Presents Pre-Clinical Data on CBL-B Program at American Association for Cancer Research Annual Meeting 2022 - HotSpot Therapeutics
- HotSpot Therapeutics Presents First-in-Human Phase 1 Clinical Data on its Novel CBL-B Inhibitor, HST-1011, at ESMO Congress 2024 - HotSpot Therapeutics
- HotSpot Therapeutics and Caris Life Sciences Announce Collaboration to Advance Precision Medicine Development for Difficult-to-Drug Therapeutic Targets - HotSpot Therapeutics
- HotSpot Therapeutics Presents Preclinical Data from Small Molecule IRF5 Inhibitor Program at 15th European Lupus Meeting - HotSpot Therapeutics
- HotSpot Therapeutics Presents Preclinical Data from Small Molecule IRF5 Program at FOCIS 2025 - HotSpot Therapeutics
- HotSpot Therapeutics Presents Preclinical Data for Potential First-in-Class MALT1 Scaffolding Inhibitor at the 4th AACR International Meeting: Advances in Malignant Lymphoma - HotSpot Therapeutics
- HotSpot Therapeutics to Present Preclinical Data from Small Molecule IRF5 Inhibitor Program at EULAR 2026 - HotSpot Therapeutics
- HotSpot Therapeutics Presents Preclinical Data from CBL-B Program at AACR Annual Meeting 2023 - HotSpot Therapeutics
- HotSpot Therapeutics to Present Preclinical Data from Small Molecule IRF5 Inhibitor Program at 15th European Lupus Meeting - HotSpot Therapeutics
- HotSpot Therapeutics Presents Preclinical Data for Potential First-in-Class MALT1 Scaffolding Inhibitor at 65th ASH Annual Meeting - HotSpot Therapeutics
- HotSpot Therapeutics Presents Additional Phase 1 Biomarker Data on Novel CBL-B Inhibitor HST-1011 at 2024 Society for Immunotherapy of Cancer Annual Meeting - HotSpot Therapeutics
- HotSpot Therapeutics Achieves First-In-Human Dosing with HST-1011, An Investigational Oral Small Molecule Allosteric Inhibitor of CBL-B - HotSpot Therapeutics
- HotSpot Therapeutics to Present Additional Preclinical Data on Potential First-in-Class MALT1 Scaffolding Inhibitor at the 4th AACR International Meeting: Advances in Malignant Lymphoma - HotSpot Therapeutics
- HotSpot Therapeutics to Present Preclinical Data from Small Molecule IRF5 Program at FOCIS 2025 - HotSpot Therapeutics
- HotSpot Therapeutics to Present Preclinical Data from Small Molecule CBM Signalosome Inhibitor Program at ESMO Gastrointestinal Cancers Congress 2025 - HotSpot Therapeutics
- HotSpot Therapeutics Appoints Alison O’Neill, M.D., as Chief Medical Officer - HotSpot Therapeutics
- HotSpot Therapeutics Appoints Paul Thibodeau, Ph.D., as Chief Business Officer - HotSpot Therapeutics
- HotSpot Therapeutics to Present Additional Phase 1 Biomarker Data on Novel CBL-B Inhibitor HST-1011 at 2024 Society for Immunotherapy of Cancer Annual Meeting - HotSpot Therapeutics
- HotSpot Therapeutics Presents Preclinical Data from MALT1 CBM Signalosome Glue Program at 36th EORTC-NCI-AACR Symposium - HotSpot Therapeutics
- HotSpot Therapeutics Presents Preclinical Data from CBL-B Program at 2022 Society for Immunotherapy of Cancer Annual Meeting - HotSpot Therapeutics
- HotSpot Therapeutics Appoints Jose Carmona to Board of Directors - HotSpot Therapeutics
- HotSpot Therapeutics to Present Preclinical Data from MALT1 CBM Signalosome Glue Program at 36th EORTC-NCI-AACR Symposium - HotSpot Therapeutics
- HotSpot Therapeutics to Present Preclinical Data from CBL-B Program at 2023 Society for Immunotherapy of Cancer Annual Meeting - HotSpot Therapeutics
- HotSpot Therapeutics to Present New Data Indicating Successful Targeting of CBL-B at 2021 Society for Immunotherapy of Cancer Annual Meeting - HotSpot Therapeutics
- HotSpot Therapeutics Closes $100M Series C to Advance First-in-Class Allosteric Drug Discovery Platform to the Clinic - HotSpot Therapeutics
- HotSpot Therapeutics to Present Initial First-in-Human Phase 1 Clinical Data on its Novel CBL-B Inhibitor, HST-1011, at ESMO Congress 2024 - HotSpot Therapeutics
- HotSpot Therapeutics Expands Board of Directors and Management Team - HotSpot Therapeutics
- HotSpot Therapeutics Presents Preclinical Data from CBL-B Program at 2023 Society for Immunotherapy of Cancer Annual Meeting - HotSpot Therapeutics
- HotSpot Therapeutics to Introduce First-in-Class MALT1 Scaffolding Inhibitor at 65th ASH Annual Meeting - HotSpot Therapeutics
- HotSpot Therapeutics to Present Pre-Clinical Data on CBL-B Program at American Association for Cancer Research Annual Meeting 2022 - HotSpot Therapeutics
- HotSpot Therapeutics to Present at the Piper Sandler 33rd Annual Healthcare Conference - HotSpot Therapeutics
- HotSpot Therapeutics Completes $65 Million Series B Financing to Advance Pipeline of Novel Allosteric Medicines - HotSpot Therapeutics
- HotSpot Therapeutics Announces FDA Clearance of IND Application for HST-1011, An Investigational Small Molecule Allosteric Inhibitor of CBL-B - HotSpot Therapeutics
- HotSpot Therapeutics to Present Two Poster Presentations on CBL-B Program at AACR Annual Meeting 2023 - HotSpot Therapeutics
- HotSpot Therapeutics Appoints Eva Jack as Chief Operating Officer - HotSpot Therapeutics
- HotSpot Therapeutics Announces Acquisition of Macroceutics, Inc. - HotSpot Therapeutics
- HotSpot Therapeutics Appoints Timothy Reilly as Chief Development Officer - HotSpot Therapeutics
- HotSpot Therapeutics to Present Preclinical Data from CBL-B Program at 2022 Society for Immunotherapy of Cancer Annual Meeting - HotSpot Therapeutics
- HotSpot Therapeutics to Present at the Solebury Trout/BMO Fall Private Company Showcase - HotSpot Therapeutics
- HotSpot Therapeutics to Present at the BMO Biopharma Spotlight Series - HotSpot Therapeutics